NT-proBNP与自报功能容量在非心脏手术后心血管事件风险评估中的比较
这项队列研究纳入欧洲25家三级医院2017年6月至2020年4月接受住院择期非心脏手术的患者,比较NT-proBNP与自报功能容量(问卷估算METs、爬1层楼能力、规律体力活动水平)加入临床评分后估计MACE风险的表现。3597例完整数据患者中86例(2.4%)发生MACE。NT-proBNP或功能容量加入临床评分后的判别能力无显著差异(AUC:RCRI+年龄+4MET为0.704;加爬楼为0.702;加体力活动为0.724;加NT-proBNP为0.736)。作者结论认为无确切证据表明两种方法存在差异。
要点
- 3597例完整数据患者中86例(2.4%)发生MACE,MACE为院内心血管死亡、心脏骤停、心肌梗死、卒中及需升级监护的充血性心力衰竭的复合终点。
- NT-proBNP加入RCRI+年龄+4MET的AUC为0.736(95%CI 0.682-0.790),与各功能容量指标加入后无显著差异。
- 功能容量三项指标加入后的AUC分别为:加爬楼0.702(95%CI 0.645-0.760)、加体力活动0.724(95%CI 0.672-0.775)。
- 获益分析在阈值5%或以下时有利于NT-proBNP,即真阳性价值为假阳性的20倍或以上时。
- 以NSQIP MICA为基线临床评分时结果相似。
适用人群与场景
- 接受住院、择期、非心脏手术的患者,来自欧洲25家三级医院,2017年6月至2020年4月。
- 纳入标准:年龄45岁及以上且RCRI为2或以上,或NSQIP MICA大于1%;或年龄65岁及以上且接受中危或高危手术。
诊断标准与关键阈值
- MACE定义:院内心血管死亡、心脏骤停、心肌梗死、卒中及需转至更高级别监护单元的充血性心力衰竭的复合终点。
- 功能容量评估包括:问卷估算代谢当量(METs)、爬1层楼能力、规律体力活动水平。
研究设计与关键结果
- 研究类型:队列研究;样本量:3731例 eligible 患者,3597例有完整数据(1258例女性[35.0%];1463例[40.7%]年龄75岁及以上;86例[2.4%]发生MACE)。
- 判别能力(AUC):RCRI+年龄+4MET为0.704(95%CI 0.646-0.763);加爬楼为0.702(95%CI 0.645-0.760);加体力活动为0.724(95%CI 0.672-0.775);加NT-proBNP为0.736(95%CI 0.682-0.790)。
- NT-proBNP或功能容量指标加入临床评分后的判别能力无显著差异。
- 获益分析在阈值5%或以下时有利于NT-proBNP,即真阳性价值为假阳性的20倍或以上时。
- 以NSQIP MICA为基线临床评分时结果相似。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在近3600例心血管风险升高的非心脏手术患者中,无确切证据表明基于NT-proBNP与基于自报功能容量的MACE风险评估存在差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Nearly 16 million surgical procedures are conducted in North America yearly, and postoperative cardiovascular events are frequent. Guidelines suggest functional capacity or B-type natriuretic peptides (BNP) to guide perioperative management. Data comparing the performance of these approaches are scarce.
OBJECTIVE: To compare the addition of either N-terminal pro-BNP (NT-proBNP) or self-reported functional capacity to clinical scores to estimate the risk of major adverse cardiac events (MACE).
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients undergoing inpatient, elective, noncardiac surgery at 25 tertiary care hospitals in Europe between June 2017 and April 2020. Analysis was conducted in January 2023. Eligible patients were either aged 45 years or older with a Revised Cardiac Risk Index (RCRI) of 2 or higher or a National Surgical Quality Improvement Program, Risk Calculator for Myocardial Infarction and Cardiac (NSQIP MICA) above 1%, or they were aged 65 years or older and underwent intermediate or high-risk procedures.
EXPOSURES: Preoperative NT-proBNP and the following self-reported measures of functional capacity were the exposures: (1) questionnaire-estimated metabolic equivalents (METs), (2) ability to climb 1 floor, and (3) level of regular physical activity.
MAIN OUTCOME AND MEASURES: MACE was defined as a composite end point of in-hospital cardiovascular mortality, cardiac arrest, myocardial infarction, stroke, and congestive heart failure requiring transfer to a higher unit of care.
RESULTS: A total of 3731 eligible patients undergoing noncardiac surgery were analyzed; 3597 patients had complete data (1258 women [35.0%]; 1463 (40.7%) aged 75 years or older; 86 [2.4%] experienced a MACE). Discrimination of NT-proBNP or functional capacity measures added to clinical scores did not significantly differ (Area under the receiver operating curve: RCRI, age, and 4MET, 0.704; 95% CI, 0.646-0.763; RCRI, age, and 4MET plus floor climbing, 0.702; 95% CI, 0.645-0.760; RCRI, age, and 4MET plus physical activity, 0.724; 95% CI, 0.672-0.775; RCRI, age, and 4MET plus NT-proBNP, 0.736; 95% CI, 0.682-0.790). Benefit analysis favored NT-proBNP at a threshold of 5% or below, ie, if true positives were valued 20 times or more compared with false positives. The findings were similar for NSQIP MICA as baseline clinical scores.
CONCLUSIONS AND RELEVANCE: In this cohort study of nearly 3600 patients with elevated cardiovascular risk undergoing noncardiac surgery, there was no conclusive evidence of a difference between a NT-proBNP-based and a self-reported functional capacity-based estimate of MACE risk.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03016936.
参考来源
- Lurati Buse G, Larmann J, Gillmann HJ, et al. NT-proBNP or Self-Reported Functional Capacity in Estimating Risk of Cardiovascular Events After Noncardiac Surgery. JAMA Netw Open. 2023. PMID: 37938844. doi:10.1001/jamanetworkopen.2023.42527
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。